4 ratings / 4.25 average

Metabolomics and IBD

Diane R Hildebrand, MB ChB, MRCS(Ed)1, Natasha P Ross, MB ChB, MRCS(Ed)1, and Angus JM Watson, MB ChB, FRCS(Ed), FRCS(Gen. Surg.)1,2

IBD is a chronic inflammatory condition with a high incidence in Northern Europe. Current biological markers are inadequate for detecting, phenotyping, and monitoring the disease. It is therefore imperative to find novel biomarkers that will not only help with diagnosis but that will also shed further light on the pathogenesis of IBD. Metabolomics is an emerging science that is increasingly being utilized for biomarker discovery. Here, we discuss the potential utility of metabolomics in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis Monit 2011;12(2):58–65.

Return to top


Complementary and Alternative Medicine in Inflammatory Bowel Disease
Louise Langmead1 and David S Rampton2
CML Gastroenterology
Is Non-Erosive Reflux Disease (NERD) an Inflammatory Condition?
Klaus Mönkemüller and Peter Malfertheiner
CML Gastroenterology
Pediatric Inflammatory Bowel Disease: An Update
Astor F Rodrigues, MRC PCH1, and David Devadason, MRC PCH2
CML Gastroenterology
Cytokine Regulation of Gut Inflammation in IBD
Thomas T MacDonald, PhD, FRCPath, FMedSci1, Iona Bell, MD1, and Giovanni Monteleone, MD2
Inflammatory Bowel Disease Monitor
The Safety of Thiopurines: New Data, New Decisions
Laurent Beaugerie, MD, Harry Sokol, MD, Philippe Seksik, MD, and Jacques Cosnes, MD
Inflammatory Bowel Disease Monitor
Managing Low-Grade Dysplasia
Aelaf D Worku, MD, and Thomas A Ullman, MD
Inflammatory Bowel Disease Monitor


Our most popular articles